More importantly, because METTL14-mediated m6A modification enhances PD-L1 expression and promotes an immunosuppressive microenvironment, inhibition of METTL14 may not only directly impair tumor proliferation but also downregulate PD-L1 expression to improve T cell–mediated antitumor immunity. The gene discussed is CD274; the disease is neoplasm.